FLT3 and acute myeloid leukemia: In addition, allo-HSCT improved survival in <i>FLT3</i>(+) AML (OS, HR 0.53; EFS, HR 0.50; RFS, HR 0.57; CIR, HR 0.26; all <i>p</i> < 0.01), which was further prolonged by FLT3i administrated after allo-HSCT (OS, HR 0.45; RFS, HR 0.34; CIR, HR 0.32; all <i>p</i> < 0.01).